235 related articles for article (PubMed ID: 27526708)
1. Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy.
Finkel KW; Cohen EP; Shirali A; Abudayyeh A;
Clin J Am Soc Nephrol; 2016 Dec; 11(12):2273-2279. PubMed ID: 27526708
[TBL] [Abstract][Full Text] [Related]
2. Treatment of acute kidney injury with cast nephropathy.
Walther C; Podoll AS; Finkel KW
Clin Nephrol; 2014 Jul; 82(1):1-6. PubMed ID: 24725380
[TBL] [Abstract][Full Text] [Related]
3. Extracorporeal treatment of cast nephropathy.
Gakhar B; Kobrin S; Berns JS
Semin Dial; 2011; 24(1):9-11. PubMed ID: 21324000
[TBL] [Abstract][Full Text] [Related]
4. High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial.
Hutchison CA; Cockwell P; Moroz V; Bradwell AR; Fifer L; Gillmore JD; Jesky MD; Storr M; Wessels J; Winearls CG; Weisel K; Heyne N; Cook M
Lancet Haematol; 2019 Apr; 6(4):e217-e228. PubMed ID: 30872075
[TBL] [Abstract][Full Text] [Related]
5. Impact of free light chain hemodialysis in myeloma cast nephropathy: a case-control study.
Peters NO; Laurain E; Cridlig J; Hulin C; Cao-Huu T; Frimat L
Hemodial Int; 2011 Oct; 15(4):538-45. PubMed ID: 22111823
[TBL] [Abstract][Full Text] [Related]
6. Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial.
Bridoux F; Carron PL; Pegourie B; Alamartine E; Augeul-Meunier K; Karras A; Joly B; Peraldi MN; Arnulf B; Vigneau C; Lamy T; Wynckel A; Kolb B; Royer B; Rabot N; Benboubker L; Combe C; Jaccard A; Moulin B; Knebelmann B; Chevret S; Fermand JP;
JAMA; 2017 Dec; 318(21):2099-2110. PubMed ID: 29209721
[TBL] [Abstract][Full Text] [Related]
7. Management of acute kidney injury in symptomatic multiple myeloma.
Bridoux F; Leung N; Belmouaz M; Royal V; Ronco P; Nasr SH; Fermand JP;
Kidney Int; 2021 Mar; 99(3):570-580. PubMed ID: 33440212
[TBL] [Abstract][Full Text] [Related]
8. Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology.
Fabbrini P; Finkel K; Gallieni M; Capasso G; Cavo M; Santoro A; Pasquali S
J Nephrol; 2016 Dec; 29(6):735-746. PubMed ID: 27757797
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study.
Sens F; Chaintreuil D; Jolivot A; Guebre-Egziabher F; Robinson P; Karlin L; Bridoux F; Juillard L
Am J Nephrol; 2017; 46(5):355-363. PubMed ID: 29017155
[TBL] [Abstract][Full Text] [Related]
10. Light Chain Cast Nephropathy: Practical Considerations in the Management of Myeloma Kidney-What We Know and What the Future May Hold.
Manohar S; Nasr SH; Leung N
Curr Hematol Malig Rep; 2018 Jun; 13(3):220-226. PubMed ID: 29725932
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Efficacy and Cost Effectiveness of High Cut-Off Dialyzers Compared to Conventional Dialysis in Patients with Cast Nephropathy.
Curti A; Schwarz A; Trachsler J; Tomonaga Y; Ambühl PM
PLoS One; 2016; 11(7):e0159942. PubMed ID: 27467401
[TBL] [Abstract][Full Text] [Related]
12. Rapid Deterioration of the Renal Function Caused by the Coexistence of Intratubular Amyloidosis and Myeloma Cast Nephropathy.
Kato H; Fujigaki Y; Asakawa S; Yamaguchi Y; Uozaki H; Komatsuda A; Nagata M; Uchida S
Intern Med; 2015; 54(23):3023-8. PubMed ID: 26631886
[TBL] [Abstract][Full Text] [Related]
13. Management options for cast nephropathy in multiple myeloma.
Cockwell P; Hutchison CA
Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):550-5. PubMed ID: 20827195
[TBL] [Abstract][Full Text] [Related]
14. Early use of PEPA dialyzer for light chains removal and for the recovery from myeloma cast nephropathy: A case report.
Donati G; Zappulo F; Croci Chiocchini AL; Comai G; Zamagni E; La Manna G
Hemodial Int; 2019 Jul; 23(3):E97-E99. PubMed ID: 30791209
[TBL] [Abstract][Full Text] [Related]
15. Use of continuous venovenous hemofiltration for acute renal failure due to multiple myeloma cast nephropathy.
Mehta S; Shtaynberg N; Goldman M; Asti D; Kiroycheva M; Pepe J
Hematology; 2012 Jul; 17(4):229-31. PubMed ID: 22889516
[TBL] [Abstract][Full Text] [Related]
16. The rationale and evidence base for the direct removal of serum-free light chains in the management of myeloma kidney.
Cockwell P; Cook M
Adv Chronic Kidney Dis; 2012 Sep; 19(5):324-32. PubMed ID: 22920643
[TBL] [Abstract][Full Text] [Related]
17. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies.
Hutchison CA; Cockwell P; Reid S; Chandler K; Mead GP; Harrison J; Hattersley J; Evans ND; Chappell MJ; Cook M; Goehl H; Storr M; Bradwell AR
J Am Soc Nephrol; 2007 Mar; 18(3):886-95. PubMed ID: 17229909
[TBL] [Abstract][Full Text] [Related]
18. [Improved prognosis in light chain nephropathy due to multiple myeloma].
Juul JS; Larsen T; Marcussen N; Pedersen EB
Ugeskr Laeger; 2012 Apr; 174(17):1159-60. PubMed ID: 22533933
[TBL] [Abstract][Full Text] [Related]
19. Treatment by long haemodialysis sessions with high cut-off filters in myeloma cast nephropathy: our experience.
Borrego-Hinojosa J; Pérez-del Barrio MP; Biechy-Baldan Mdel M; Merino-García E; Sánchez-Perales MC; García-Cortés MJ; Ocaña-Pérez E; Gutiérrez-Rivas P; Liébana-Cañada A
Nefrologia; 2013; 33(4):515-23. PubMed ID: 23897183
[TBL] [Abstract][Full Text] [Related]
20. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains.
Leung N; Gertz MA; Zeldenrust SR; Rajkumar SV; Dispenzieri A; Fervenza FC; Kumar S; Lacy MQ; Lust JA; Greipp PR; Witzig TE; Hayman SR; Russell SJ; Kyle RA; Winters JL
Kidney Int; 2008 Jun; 73(11):1282-8. PubMed ID: 18385667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
